The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Abstract Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosi...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessica A. Moerland, Di Zhang, Lyndsey A. Reich, Sarah Carapellucci, Beth Lockwood, Ana S. Leal, Teresa Krieger-Burke, Bilal Aleiwi, Edmund Ellsworth, Karen T. Liby
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
R
Q
Online Access:https://doaj.org/article/6d8fd743dcf44e9bbf89c3d1f8bcd6a9
Tags: Add Tag
No Tags, Be the first to tag this record!